Capital Return / Corporate Action
Aurobindo Pharma Announces ₹800 Crore Buyback at ₹1,475 per Share
NSE
auropharma
BSE
524804
Aurobindo Pharma has approved a share buyback worth ₹800 crore at ₹1,475 per share, representing up to 0.93% of its equity capital, signaling confidence in its financial position.
PRICE-SENSITIVE TRIGGER
Event: Share Buyback Announcement
Type: Capital Return / Corporate Action
Impact: Positive
Immediate Effect: Supports stock price and enhances shareholder value.
Key Metrics
- Buyback Size: ₹800 Crore
- Buyback Price: ₹1,475 per share
- Shares to be Bought Back: 54,23,728 shares
- % of Equity: 0.93%
- Mode: Tender Offer
- Consideration: Cash
Timeline
- Record Date: April 17, 2026
- Completion: As per regulatory process
Highlights
Buyback Price: ₹1,475 per share
What Happened ?
Aurobindo Pharma Limited announced that its Board has approved a share buyback of up to ₹800 crore through the tender offer route.
The buyback will be executed at a price of ₹1,475 per share, offering shareholders an opportunity to exit at a premium.
Key highlights
Capital Return
- ₹800 crore cash outflow
- Improves shareholder returns
- Reduces excess cash reserves
Shareholder Value
- Buyback price often at premium
- Potential EPS improvement
- Supports stock valuation
Ownership Impact
- Buyback size:
- 0.93% of equity
- Promoters eligible to participate
Strategic Intent
- Reflects:
- Strong balance sheet
- Management confidence
Note: Small % buyback → sentiment positive but limited EPS impact.
Risk Analysis
Key Risks
- Limited size (only 0.93%)
- Opportunity cost of capital
- Market expectations vs actual benefit
Worst Case Scenario
If premium is low, buyback may not significantly impact stock price.
Risk Level: Low
Company Commentary
- Focus on capital efficiency
- Returning surplus cash to shareholders
- Strengthening investor confidence
Official Exchange Filing: Aurobindo Pharma Limited